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Abstract
Congenital adrenal hyperplasia (CAH) is one of the most prevalent, and potentially
severe, genetic inborn errors of steroid synthesis directly affecting metabolism. Most
patients are diagnosed and treated at an early age. There have been very limited reports
of adults with CAH-associated adrenal myelolipomas. We aimed to analyze two families
with CAH-associated giant adrenal myelolipomas caused by defects in CYP21A2 and
CYP17A1 genes. A total of 14 individuals from two unrelated families were identified
with either CYP21A2 or CYP17A1 mutations. Of note, five patients were found with
adrenal myelolipomas. Total DNA isolated from the peripheral blood of the two
probands was screened for potential mutations in the following susceptibility genes of
CAH: CYP21A2, CYP11B1, CYP17A1, HSD17B3, HSD3B2, ARMC5, and STAR using target
capture-based deep sequencing; and Sanger sequencing was conducted for the family
members to detect the potential mutations. The following results were obtained. In
family 1, molecular genetics sequencing revealed a compound heterozygous mutation
(c.293-13C>G/c.518T>A, p.I173N) in CYP12A2 in the patient and his brother. In family 2,
all three female patients with adrenal myelolipomas were found to have a compound
heterozygous mutation (c.1118A>T, p.H373L/c.1459_1467del9, p.D487_F489del) in
CYP17A1. To avoid giant CAH-associated adrenal myelolipomas in adults, it is important
to identify CAH early so that appropriate treatment can be initiated to interrupt the
chronic adrenal hyperstimulation resulting from increased ACTH. Genetic testing and
counseling could be useful in CAH.
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Introduction
Congenital adrenal hyperplasia (CAH) is one of the
most severe disorders of metabolism with an overall
incidence of approximately 1:15,000 worldwide (1). CAH
encompasses a group of enzymatic deficiencies of cortisol
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synthesis, inherited in an autosomal recessive manner.
Defective cortisol production results in negative feedback
at the hypothalamus and pituitary gland, leading to
excessive secretion of corticotrophin-releasing hormone
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and adrenocorticotropic hormone (ACTH), respectively.
Increased levels of ACTH are not only unable to compensate
for the deficient cortisol synthesis, but their trophic effects
also produce adrenal gland enlargement (2).
Pathologically, CAH is mainly caused by an inborn error
of steroid synthesis. Six cytochrome P450 (CYP) enzymes
including CYP11A1, CYP11B1, CYP11B2, CYP17A1,
CYP19A1 and CYP21A2 are involved in the synthesis of
steroid hormones. Although deficiencies of any of these
enzymes can result in CAH (3), CYP21A2 deficiency
(21OHD) accounts for up to 95% of all CAH cases (4).
The CYP21A2 gene is located on 6p21.3, approximately
30 kb from its pseudogene (CYP21A1P). CYP21A2
and CYP21A1P share approximately 98% homology
in their exons and 96% homology in their introns;
therefore, a high frequency of recombination events
may occur between the gene and pseudogene, leading
to varying degrees of CYP21A2 enzymatic deficiency.
Complete deficiency of CYP21A2 activity leads to both
glucocorticoid and mineralocorticoid deficiencies, as well
as severe adrenal-derived androgen excess, resulting in the
virialized external genitalia of newborn girls. Compared
to CYP21A2-related disorders, CYP17A1 deficiency is rare.
The CYP17 gene is located on chromosome 10q24-q25
and encodes 17α-hydroxylase, which catalyzes the
17α-hydroxylation of pregnenolone and progesterone and
the 17,20-cleavage of the corresponding hydroxylated
steroids (5). CYP17A1 deficiency leads to the impaired
synthesis of both glucocorticoids and androgen, resulting
in increased ACTH secretion. Patients present with
hypertension, hypokalemia and hypogonadism. Both
46, XY and 46, XX individuals have feminine external
genitalia and present with amenorrhea and absent
secondary sexual characteristics during puberty (2).
Adrenal myelolipomas are rare, benign and
endocrinologically inactive neoplasms composed of
mature fat tissue and mixed myeloid and erythroid
tissue (6). They account for approximately 8% of adrenal
incidentalomas (6). In most cases, adrenal myelolipomas
are unilateral and rarely exceed 4 cm. However, very
large and bilateral myelolipomas have been reported,
especially in the setting of CAH (7). Although these
tumors are benign, huge masses can produce symptoms
such as flank pain and abdominal discomfort because
of rupture, hemorrhage or necrosis (7). Some patients
with giant adrenal myelolipomas may present with
even more severe symptoms, including hematuria,
renovascular hypertension and surgical emergencies such
as retroperitoneal hemorrhage (8). CAH and Cushing’s
syndrome are two of the most common causes of adrenal
https://ec.bioscientifica.com
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myelolipomas (9), and 4% of patients with CAH will
develop a myelolipoma (10). In this report, we describe
two adult families with CAH-associated giant adrenal
myelolipomas secondary to compound heterozygous
mutations in CYP21A2 and CYP17A1 genes.

Materials and methods
Patients
A total of 15 individuals from two unrelated families were
sequenced to evaluate whether they carried the mutations
or not. Among them, 14 individuals were identified with
either CYP21A2 or CYP17A1 mutations. Of note, five
patients were found with adrenal myelolipomas. The
medical records including CT or MRI scan and laboratory
/pathological examinations, as well as gene sequencing
results were collected and analyzed. Additional
information regarding their family history was obtained
by further interviewing.
Compliance with ethical standards
All procedures involving human participants were
carried out in accordance with the ethical standards
of the institutional research committee and with the
1964 Helsinki Declaration and its later amendments or
comparable ethical standards. The Daping Hospital of
Third Military Medical University waived institutional
review board approval for the study; however, written
informed consent for the use of medical records and
related images was obtained from the patients.
Genetic analysis
Total DNA isolated from the peripheral blood of the two
probands was screened for potential mutations in the
following susceptibility genes of CAH: CYP21A2, CYP11B1,
CYP17A1, HSD17B3, HSD3B2, ARMC5 and STAR using
Target Capture-Based Deep Sequencing (AmCare Genomic
Laboratory, Guangzhou, Guangdong, China). Briefly,
the process included fragmentation and construction of
a genomic DNA, hybridization with custom made probe
library (Nimblegen, Roche) to capture the genes of interested.
The sequencing was carried out on NGS platform (HiSeq X
system; Illumina) with PEx150 read length according to the
manufactory’s specification. The bioinformatics analysis
was performed with in-house pipeline to identify rare or
novel variants with Gnomad, HMGD, ClinVar, dbSNP
for filtering and computational prediction algorithms,
This work is licensed under a Creative Commons
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PolyPhen-2, SIFT and MutationTaster, for pathogenesis
evaluation. After the identification of the variants in the
proband, family co-segregation analyses were performed
using Sanger sequencing. The corresponding primers
were designed by Primer 3.0 and available upon request.
The final pathogenicity of the variants was estimated
using the American College of Medical Genetics and
Genomics guidelines.

Results
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On April 26, 2012, the patient underwent open bilateral
adrenalectomies. Intraoperative findings revealed a 1.56 kg
mass in the left adrenal and a 3.05 kg mass in the right
adrenal (Fig. 1A, right lower corner). Pathology results
confirmed the presence of bilateral adrenal myelolipomas
(Fig. 1C and D). The patient’s older brother had previously
undergone bilateral adrenalectomies in 1989 at the age of
50 years for pathology confirmed adrenal myelolipomas.
Their parents died early with unknown cause. The other
family members were screened for the disease by CT or
MRI, as well as hormonal testing. No abnormality was
found.

Clinical features of the patients
Family 1
A 59-year-old man was referred to our hospital in
April 2012 with abdominal pain. CT revealed low
attenuated masses in both adrenal glands (Fig. 1A). On
admission, his blood pressure was 132/78 mmHg and
heart rate was 78 beats/min. His physical examination
was unremarkable, revealing no signs of Cushing’s
syndrome, hyperaldosteronism or pheochromocytoma.
Laboratory results demonstrated elevated levels
of 17-hydroxycorticosteroid (17-OH; 38.5 μmol/24 h,
normal
8.3–33.2 μmol/24 h)
and
17-ketosteroid
(7-KS; 98.8 μmol/24 h, normal 20.8–76.3 μmol/24 h).

Family 2
A 36-year-old woman presented to the affiliated hospital
of Nanjing University of Traditional Chinese Medical
with fatigue, headaches and asyndesis (unspeakable) in
March 2012. She had hypokalemia since childhood and
hypertension for the past 6 years. On admission, her
blood pressure was 170/110 mmHg. MRI revealed bilateral
adrenal masses with a signal intensity similar to that of
fat, suggesting the presence of adrenal myelolipomas
(Fig. 1B). Laboratory results showed increased ACTH
(more than 1250 pg/mL) and decreased cortisol (less
than 2 μg/dL). In April and November 2012, the patient

Figure 1
Representative CT scan, MRI scan and
hematoxylin and eosin (H & E) staining of the
presenting patients (probands) in each family.
(A) CT and MRI images showing bilateral adrenal
masses in the proband for family 1. The adrenals
removed during surgery are shown in the right
lower corner. (B) MRI scan showing bilateral
adrenal masses in the proband for family 2.
(C and D) H & E staining of the masses in the
proband for family 1. Magnification: ×100 (C),
×400 (D).
https://ec.bioscientifica.com
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underwent left and right adrenalectomies, respectively.
Intraoperative findings showed a 20 cm × 15 cm × 10 cm
mass in the left adrenal and another smaller mass in the
right adrenal.
In June 2012, the patient’s 32-year-old sister was
referred to the affiliated hospital of Nanjing University of
Traditional Chinese Medical because of increased fatigue.
She had presented with fatigue 8 years before, at which
time she was found to have hypokalemia. CT scan revealed
a mass in her left adrenal. Laboratory results showed
increased ACTH (271 pg/mL) and decreased cortisol
(less than 2 μg/dL). In October 2012, she underwent left
adrenalectomy, and the pathology results revealed an
adrenal myelolipoma.
In July 2012, the patient’s 37-year-old sister was
also referred to the affiliated hospital of Nanjing
University of Traditional Chinese Medical. She had
hypertension and hypokalemia for the previous 3 years.
CT scan revealed bilateral adrenal masses. Laboratory
results showed increased ACTH (503 pg/mL) and
decreased cortisol (3.1 μg/dL). In July and December
2012, she underwent left and right adrenalectomies,
respectively. Pathology results confirmed the presence
of adrenal myelolipomas. The other family members
were asymptomatic on CT or MRI.
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Identification of the mutations
Family 1
Considering the positive family history, CAH was
suspected and genomic analysis was performed using DNA
isolated from peripheral blood leukocytes. A compound
heterozygous mutation, consisting of c.293-13C>G and
c.518T>A, p.I173N, was identified in the CYP12A2 gene
(Fig. 2A). Sanger sequencing of the CYP12A2 gene was
conducted in the family members. The brother had the
same compound heterozygous mutation as the patient.
The patient’s sister exhibited only the c.518T>A, p.I173N
mutation. Two of the patient’s daughters had only the
c.293-13C>G mutation, while another daughter and her
daughter had only the c.518T>A, p.I173N mutation.
The daughter of the patient’s brother carried only the
c.293-13C>G mutation. The family pedigree is shown
in Fig. 2C.
Family 2
Considering the positive family history, CAH was suspected.
Genomic sequencing of the patient revealed a compound
heterozygous mutation, consisting of c.1118A>T, p.H373L,
and c.1459_1467del9, p.D487_F489del in the CYP17A1 gene
(Fig. 2B). Sanger sequencing was conducted on the family

Figure 2
Gene sequencing data and family pedigrees.
(A and B) Compound heterozygous mutations in
CYP21A2 gene in family 1 (A) and in CYP17A1
gene in family 2 (B). (C and D) Pedigrees for
families 1 (C) and 2 (D). The red arrow indicates
the proband. ‘?’ represents that the patients were
not conducted with gene sequencing.
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members, and the patient’s two sisters were found to have
the same compound heterozygous mutation. Her father and
asymptomatic brother carried only the c.1118A>T, p.H373L
mutation, and her mother had only the c.1459_1467del9,
p.D487_F489del mutation. The family pedigree is
shown in Fig. 2D.

Discussion
A few cases of CAH-associated adrenal myelolipoma
have been reported previously with most of them
caused by 21-OH deficiency. The second most common
cause was 17-OH deficiency (11). In the current report,
two patients in family 1 presented with CAH-associated
giant adrenal myelolipomas secondary to 21-OH
deficiency caused by a compound heterozygous mutation
(c.293-13C>G/c.518T>A,
p.I173N).
Three
patients
in family 2 presented with CAH-associated adrenal
myelolipomas because of 17-OH deficiency resulting
from a compound heterozygous mutation (c.1118A>T,
p.H373L/c.1459_1467del9, p.D487_F489del). All the
four mutations have been reported to be associated with
CAH, respectively (12, 13, 14, 15). However, no adrenal
myelolipoma was found with single mutations. Here,
we firstly described these two compound heterozygous
mutations in two unrelated families and found that only
these compound heterozygous mutations, but not the
single mutation, in the CYP genes can result in adrenal
myelolipomas.
A previous study reported that approximately
65–75% of CAH patients had compound heterozygous
mutations, and the phenotype correlated with the less
severely mutated allele (16). However, our results suggest
that CAH-associated adrenal myelolipomas occurred
only when compound heterozygous mutations were
present. In addition, the adrenal myelolipomas caused by
21-OH deficiency seemed to occur at an older age than
those caused by 17-OH deficiency, as the individuals in
family 1 were diagnosed with adrenal myelolipomas at
approximately 50–60 years of age, whereas those in family
2 were diagnosed at 30–40 years of age. A previous report
noted that most adrenal myelolipomas due to 17-OH
deficiency were unilateral (11). However, the mutations
(H373L/D487_F489del) in family 2 tended to produce
bilateral adrenal myelolipomas; the youngest sister
presented with a tumor that was unilateral, but this may
have been because of her younger age.
Notably, chronic ACTH hyperstimulation is thought to
trigger metaplasia in CAH-associated adrenal myelolipomas,
https://ec.bioscientifica.com
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as more myelolipomas have been described in the setting
of ACTH-excess CAH (17). Although benign, CAHassociated adrenal myelolipomas may grow rapidly when
exposed to chronically elevated ACTH levels for extended
period (18). Most patients in previous reports were either
untreated or had stopped taking their CAH medications for
an extended period (19). The patients in our report were
all untreated for a prolonged period of time, which led to
chronic ACTH hyperstimulation and subsequent adrenal
myelolipomas. Therefore, to avoid giant CAH-associated
adrenal myelolipomas, it is important to identify CAH
as early as possible to begin appropriate treatment and,
thereby, interrupt the chronic adrenal hyperstimulation
resulting from increased ACTH levels.
Although adrenal myelolipomas were seen in
both families with different phenotypes. For example,
hypertension and hypokalemia were observed in only
family 2. The divergent phenotypes reflected the presence
of mutations in different genes, CYP21A2 and CYP17A1.
CYP21A2 deficiency produces reduced aldosterone and
cortisol and excess testosterone, whereas CYP17A1
deficiency leads to decreased cortisol and testosterone
and increased aldosterone, which causes hypertension
and hypokalemia (2). In the same family, members with
concurrent mutations in both alleles presented with
adrenal myelolipomas, whereas individuals with either
mutation in just one allele did not. This difference in
tumor occurrence may be due to varying degrees of
enzymatic deficiency. A previous study found that patients
with severe mutations causing complete deficiency of
enzymatic activity presented with severe phenotypes,
whereas patients with mild mutations exhibited the nonclassical form of CAH (20). In vitro expression analysis
demonstrated that complete deficiency of 21-hydroxylase
enzymatic activity could result from multiple mutations
in the CYP21A2 gene, such as large deletion Δ707-714,
Q318X and R356W mutations. These mutations could
cause severe phenotypes, whereas other mutations,
including P30L (89 C to T), V281L (1685 G to T) and
P453S (2580 C to T) mutations, may lead to 20–60%
residual enzymatic activity, which is likely to produce a
moderate phenotype (20). Furthermore, a previous study
reported that patients with the classical form of CAH most
commonly had an IVS2 AS-13 (A/C to G) mutation and
a large deletion in the CYP21A2 gene (20). These results
indicate that a strong genotype–phenotype correlation
exists in CAH. Therefore, individuals with the compound
mutations described in the current report should be
treated early to avoid chronic ACTH hyperstimulation
and actively monitored for adrenal myelolipomas.
This work is licensed under a Creative Commons
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This highlights the importance of genetic testing and
counseling in CAH-associated adrenal myelolipomas.
In conclusion, we found that compound heterozygous
mutations, but not the single mutation, in the CYP
genes can result in adrenal myelolipomas. Our finding
also suggests that early diagnosis and timely treatment
for chronic adrenal hyperstimulation may prevent
the development of giant CAH-associated adrenal
myelolipomas. In addition, genetic testing and counseling
could be valuable means in dealing with CAH.
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